Sihuan Pharmaceutical (HKG:0460) expects to record a maximum loss of 600 million yuan and a minimum revenue of 1.80 billion yuan for 2024, a Monday bourse filing said.
The company attributed its financial results for the reporting year to a decline in its generic drug business, high research and development costs for its innovative drugs, and certain one-off expenses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.